Michael Grusch Selected Research

Adenocarcinoma of Lung

1/2021	EGF Induces Migration Independent of EMT or Invasion in A549 Lung Adenocarcinoma Cells.
8/2016	Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.
3/2016	High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.
5/2015	Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma.
7/2014	Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
1/2013	Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Grusch Research Topics

Disease

69	Neoplasms (Cancer) 01/2022 - 08/2002
12	Malignant Mesothelioma 06/2022 - 05/2011
12	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 11/2003
10	Neoplasm Metastasis (Metastasis) 10/2020 - 11/2012
10	Melanoma (Melanoma, Malignant) 01/2020 - 12/2010
9	Leukemia 01/2015 - 08/2002
7	Breast Neoplasms (Breast Cancer) 01/2017 - 12/2010
6	Adenocarcinoma of Lung 01/2021 - 01/2013
6	Colorectal Neoplasms (Colorectal Cancer) 12/2020 - 08/2004
6	Mesothelioma 08/2020 - 05/2011
6	Carcinoma (Carcinomatosis) 01/2018 - 01/2001
5	Inflammation (Inflammations) 07/2015 - 11/2006
5	Colonic Neoplasms (Colon Cancer) 11/2012 - 08/2004
4	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 09/2008
4	Ovarian Neoplasms (Ovarian Cancer) 10/2016 - 07/2009
3	Lung Neoplasms (Lung Cancer) 12/2018 - 08/2016
3	Pancreatic Neoplasms (Pancreatic Cancer) 10/2013 - 02/2008
3	Liver Neoplasms (Liver Cancer) 03/2011 - 11/2006
3	Necrosis 01/2006 - 04/2002
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2021 - 08/2016
2	Rectal Neoplasms (Rectal Cancer) 01/2019 - 10/2016
2	Nevus (Nevi) 10/2017 - 01/2015
2	Sarcoma (Soft Tissue Sarcoma) 10/2016 - 09/2015
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 08/2015 - 01/2015
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2013 - 10/2008
2	Carcinogenesis 12/2010 - 03/2008
2	Liver Cirrhosis (Hepatic Cirrhosis) 10/2009 - 11/2006
2	Lymphoma (Lymphomas) 03/2009 - 07/2005
2	Fibrosis (Cirrhosis) 03/2008 - 11/2006

Drug/Important Bio-Agent (IBA)

13	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2022 - 10/2008
11	Proteins (Proteins, Gene)FDA Link 01/2020 - 11/2003
11	DNA (Deoxyribonucleic Acid)IBA 09/2019 - 04/2002
10	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 10/2013 - 08/2002
9	Biomarkers (Surrogate Marker)IBA 10/2020 - 10/2009
8	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2015 - 08/2002
7	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 01/2022 - 01/2008
7	activin AIBA 11/2021 - 11/2006
7	ResveratrolIBA 10/2013 - 10/2006
6	Pharmaceutical PreparationsIBA 10/2020 - 03/2011
6	Biological ProductsIBA 10/2018 - 11/2003
6	EnzymesIBA 05/2015 - 08/2002
5	LigandsIBA 01/2022 - 01/2014
5	Messenger RNA (mRNA)IBA 01/2022 - 04/2012
5	Type 4 Fibroblast Growth Factor ReceptorIBA 01/2022 - 01/2014
5	Epidermal Growth Factor (EGF)IBA 01/2021 - 01/2006
5	Phosphotransferases (Kinase)IBA 01/2018 - 10/2014
5	Small Interfering RNA (siRNA)IBA 12/2015 - 01/2008
4	FollistatinIBA 11/2021 - 11/2006
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021 - 01/2006
4	Protein Isoforms (Isoforms)IBA 01/2020 - 10/2011
4	Activins (Activin)IBA 01/2016 - 11/2003
4	ErbB Receptors (EGF Receptor)IBA 05/2015 - 10/2008
3	Tyrosine Kinase InhibitorsIBA 01/2020 - 05/2015
3	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 01/2020 - 12/2015
3	VemurafenibIBA 09/2019 - 01/2017
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2019 - 07/2009
3	Gallic AcidIBA 09/2019 - 01/2007
3	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2018 - 10/2011
3	nintedanibIBA 01/2018 - 08/2016
3	AvemarIBA 03/2009 - 02/2005
3	StilbenesIBA 06/2008 - 10/2006
2	IntegrinsIBA 01/2022 - 10/2015
2	MicroRNAs (MicroRNA)IBA 12/2019 - 01/2018
2	PD 173074IBA 12/2018 - 06/2017
2	CaspasesIBA 10/2018 - 11/2003
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2018 - 01/2017
2	AZD 6244IBA 05/2018 - 01/2017
2	Calcium-Transporting ATPases (Ca2+ ATPase)IBA 01/2017 - 01/2017
2	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 08/2016 - 09/2015
2	Anaplastic Lymphoma KinaseIBA 08/2015 - 01/2015
2	Methylene Chloride (Dichloromethane)IBA 07/2015 - 04/2009
2	Fatty Acid Synthases (Fatty Acid Synthase)IBA 05/2015 - 07/2009
2	PolyphenolsIBA 01/2015 - 10/2009
2	triphosphoric acid (triphosphate)IBA 01/2015 - 12/2010
2	Mitogen-Activated Protein KinasesIBA 10/2014 - 12/2010
2	Hormones (Hormone)IBA 03/2014 - 09/2007
2	major vault proteinIBA 11/2013 - 06/2012
2	digalloylresveratrolIBA 10/2013 - 02/2009
2	Green Fluorescent ProteinsIBA 01/2012 - 06/2010
2	Canertinib (CI 1033)IBA 09/2011 - 07/2009
2	EKB 569IBA 09/2011 - 07/2009
2	Deferoxamine (Desferal)FDA LinkGeneric 03/2011 - 01/2001
2	3,3',4,5'-tetrahydroxystilbeneIBA 12/2010 - 10/2008
2	ProteomeIBA 06/2010 - 01/2010
2	Fluorouracil (Carac)FDA LinkGeneric 02/2009 - 08/2004
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 02/2009 - 01/2007
2	Heparin (Liquaemin)FDA LinkGeneric 12/2008 - 01/2006
2	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 12/2008 - 01/2006
2	Deuterium Oxide (Heavy Water)IBA 02/2008 - 09/2005
2	Floxuridine (FUdR)FDA LinkGeneric 07/2005 - 08/2004
2	Transferrin (beta 2 Transferrin)IBA 11/2003 - 01/2001
1	Angiogenesis InhibitorsIBA 06/2022
1	ParaffinIBA 04/2021
1	Formaldehyde (Formol)FDA Link 04/2021
1	Immune Checkpoint InhibitorsIBA 04/2021

Therapy/Procedure

24	Therapeutics 10/2020 - 02/2008
11	Drug Therapy (Chemotherapy) 01/2018 - 08/2002
4	Radiotherapy 09/2019 - 05/2011
2	Immunotherapy 04/2021 - 09/2019
2	Neoadjuvant Therapy 01/2019 - 10/2016